These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29290125)

  • 21. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Apr; 78(4):801-803. PubMed ID: 29017843
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
    Takamura S; Sugai S; Taguchi R; Teraki Y
    J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
    J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    Br J Dermatol; 2019 Jan; 180(1):211-212. PubMed ID: 30120892
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.
    Lee EB; Amin M; Egeberg A; Wu JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):e393-e394. PubMed ID: 29730885
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
    J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
    Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.